Loading video...
Video Failed to Load
Pfizer is advancing obesity science. New Phase 2b data for our investigational GLP‑1 RA peptide show robust efficacy and favourable GI tolerability across weekly and monthly dosing, supporting our extensive pivotal program. Learn more: [link] #ADASciSessions #Obesity #GLP1 #ClinicalTrials #Innovation #Healthcare
11,700 views • 3 months ago •via X (Twitter)
0 Comments
No comments available
Comments from the original post will appear here



